Britain’s pharma giants: AstraZeneca’s oncology momentum against GSK’s vaccines-and-medicines balance.

Both draw from the same market; the difference is the quality of the pipeline and the pace of growth. AstraZeneca carries clearer oncology momentum and a richer late-stage pipeline, while GSK balances vaccines and medicines at a more cautious valuation — growth against steadiness.